What is drug negotiation?
Recently, Ministry of Human Resources and Social Security issued the Notice on Incorporating 36 Drugs into Category B of the National Drug List of Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (hereinafter referred to as the Notice), which included 36 negotiated drugs into Category B of the new version of the Basic Medical Insurance Drug List of 20 17, and simultaneously determined the medical insurance payment standards for these drugs.
The negotiation of medical insurance drug list access, referred to as drug negotiation, is aimed at some expensive patents and drugs exclusively produced by manufacturers, and it is also a common practice of international medical insurance management to allow them to enter the medical insurance drug list on the premise of reducing prices through negotiation.
For manufacturers, drugs that are successfully negotiated can get more purchases because they enter medical insurance; For the medical insurance fund, price reduction can not only expand the coverage of medical insurance, but also reduce the risk of fund operation; Patients with high medical pressure can get double benefits of price reduction and medical insurance payment.
Which drugs failed to negotiate?
According to official information, eight kinds of drugs entered the list of drugs negotiated in Ministry of Human Resources and Social Security, but ultimately failed to be included in the medical insurance through negotiation, and the price was exchanged for the quantity.
Five of the eight drugs that failed to negotiate were made in China: Xinmailong injection from Yunnan Tengyao Pharmaceutical Co., Ltd., Eurekalin for injection from Guangdong Pu Tian Biochemical Pharmaceutical Co., Ltd., paclitaxel liposome for injection from Luye Pharmaceutical Group Co., Ltd., Yiqifumai (freeze-dried) for injection from Tasly Group and Xuebijing injection from Tianjin Hongri Pharmaceutical Co., Ltd.
In addition, cetuximab injection from Merck China, Bosentan tablets from Aktai Pharmaceutical Company and infliximab for injection from Xi Anrang Sang Pharmaceutical Co., Ltd. are also listed.
In an interview with Southern Reporter, a pharmaceutical company that failed in negotiation and did not want to be named admitted that there was no problem with the safety and efficacy of the company's products. At this level, it was not shortlisted, mainly because the negotiated price could not cover the cost.
AstraZeneca entered three places this time, second only to Roche in the number of finalists. Sun Xiaoyun, its public relations director, told Southern Reporter that the company has been actively supporting the national drug negotiations and will actively discuss the reimbursement ratio with the provinces. She said that this time, the company was shortlisted for chronic diseases, and the drug base was good.
From the perspective of medicine, the market prospects of diabetes, macromolecular anti-tumor targeted drugs, small molecular anti-tumor targeted drugs and tinib drugs will be relatively clear after being shortlisted.
Take trastuzumab for the treatment of breast cancer. Because of the high incidence of breast cancer in recent years, the drug is widely used at its own expense. After this price reduction, it is expected that there will be further heavy volume.
I hope that relevant measures will be implemented as soon as possible, so that it is no longer difficult for our people to see a doctor.